FIG. 7.

Inhibition of GSK-3β by its inhibitor attenuated diabetes-induced changes related to glucose and lipid metabolism. Once diabetes was diagnosed on day 3 after mice were injected with STZ, half of these diabetic mice were immediately administered GSK-3β–specific inhibitor SB216763 at 600 μg/kg every other day for 2 months, and then cardiac glycogen synthase (GS) phosphorylation (A), HK II expression (B), PPARα expression (C), and PGC-1α expression (D) were examined by Western blotting. Cardiac lipid accumulation was examined by Oil Red O staining (400×) (E). *P < 0.05 vs. corresponding controls; #P < 0.05 vs. corresponding diabetes. (A high-quality digital representation of this figure is available in the online issue.)